November 16, 2012 at 06:09 AM EST
Innovent Biologics Raises $25 Million for Suzhou cGMP Manufacturing Plant
Innovent Biologics, a Suzhou antibody develop and manufacturing company, officially announced a $25 million Series B financing. The investors were Lilly Asia Ventures and two Fidelity funds: Fidelity Biosciences and Fidelity Growth Partners Asia. Innovent is using the money to build a new campus in Suzhou Biobay that will house monoclonal antibody lab and manufacturing facilities. More details.... Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});  
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here